AAELIX Therapeutics
AELIX Therapeutics is a Barcelona-based clinical-stage biotech spun off from HIVACAT that develops the HTI immunogen, a therapeutic HIV vaccine designed to help achieve functional HIV cure/eradication. In November 2024 Gilead Sciences acquired AELIX's HTI HIV vaccine investigational assets; the company now appears to operate with a very small team (~2 employees).
SectorsBiotechnology, HIV Therapeutics, Vaccines & Immunotherapy
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
B
Bonaventura Clotet
Co-Founder
C
Christian Brander
Co-Founder & Chief Scientific Officer
J
Jordi Naval
Co-Founder & Board Director
J
Josep Maria Gatell
Co-Founder
Global models 5
MModerna
United States · www.modernatx.com ↗
mRNA-based vaccine and immunotherapy platform, including infectious-disease vaccine programs analogous to AELIX's therapeutic vaccine approach.
$2.6BComparable
IImmunocore
United Kingdom · www.immunocore.com ↗
T-cell receptor-based immunotherapy platform targeting infectious disease and cancer, similar immune-engineering approach to AELIX's T-cell-directed HTI vaccine.
$320MComparable
GGritstone bio
United States · www.gritstonebio.com ↗
Developed a neoantigen/T-cell-based vaccine platform including an HIV vaccine program, directly comparable to AELIX's therapeutic HIV vaccine model.
$194MComparable
E
Excision BioTherapeutics
United States · www.excisionbio.com ↗
Clinical-stage biotech developing a gene-editing based HIV cure therapy, same HIV-cure/eradication strategic goal as AELIX.
$150MComparable
AAmerican Gene Technologies
United States · www.americangene.com ↗
Gene-therapy company pursuing a functional HIV cure, targeting the same therapeutic HIV cure market as AELIX's HTI vaccine.
$81.3MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 6
Open as list →
YYsios Capital
ysioscapital.com
CCriteria Capital Risc
www.caixacapitalrisc.es
CCentro para el Desarrollo Tecnológico y la Innovación
www.cdti.es
E
EIT Health
eithealth.eu
J
Johnson & Johnson Innovation - JJDC
1
10K Lakes Capital
Funding rounds 2
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2021-09-15 | Series A (estimated) | €1.86M |
Lead not disclosed
+3 more
|
| 2016-01-11 | Series A | €11.5M |
Ysios Capital
+2 more
|
News 3
Open as list →| Published | Article |
|---|---|
| 2025-08-19 |
Meet 10 biotech companies you can't miss in Spain in 2025 ↗
Labiotech.eu
2025-08-19 |
| 2024-11-26 |
Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech ↗
Pharmaceutical Technology
2024-11-26 |
| 2023-02-22 |
AELIX Therapeutics announces positive results on HIV trial ↗
Labiotech.eu
2023-02-22 |